Medical grade honey as a promising treatment to improve ovarian tissue transplantation

Detalhes bibliográficos
Autor(a) principal: Azevedo, Ana Rita
Data de Publicação: 2022
Outros Autores: Pais, Ana Sofia, Almeida-Santos, Teresa, Pires, Virgínia M. R., Pessa, Pedro, Marques, Carla C., Nolasco, Sofia, Castelo-Branco, Pedro, Prates, José A. M., Lopes-da-Costa, Luís, Laranjo, Mafalda, Botelho, Maria Filomena, Pereira, Rosa M. L. N., Pimenta, Jorge M. B. G. A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/18727
Resumo: Ovarian tissue cryopreservation is a female fertility preservation technique that presents major challenges for the maintenance of follicular viability after transplantation. The aim of this study was to evaluate and compare the application of L-Mesitran Soft(R), a product containing 40% medical grade honey (MGH), with other strategies to improve ovarian grafts' viability. For this purpose, bovine ovarian tissue was vitrified, warmed and randomly assigned to culture groups: (1) control, (2) MGH 0.2% in vitro, (3) MGH in vivo (direct application in the xenotransplantation), (4) vascular endothelial growth factor (VEGF 50 ng/mL) and (5) vitamin D (100 Nm), during a 48 h period. A sixth group (6) of fragments was thawed on transplantation day and was not cultured. The tissue was xenotransplanted into immunodeficient (Rowett nude homozygous) ovariectomized rats. Grafts were analyzed 48 h after culture, and 7 and 28 days after transplantation. The tissue was subjected to histological and immunohistochemical analysis. Treatments using MGH showed the highest angiogenic and cell proliferation stimulation, with cellular apoptosis, within a healthy cellular turnover pathway. In conclusion, MGH should be considered as a potentially effective and less expensive strategy to improve ovarian tissue transplantation.
id RCAP_e31d81645ad31f8cc3c16b86028b7d17
oai_identifier_str oai:sapientia.ualg.pt:10400.1/18727
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Medical grade honey as a promising treatment to improve ovarian tissue transplantationXenograftingOvarianVitrificationHoneyFertilityCryopreservationOvarian tissue cryopreservation is a female fertility preservation technique that presents major challenges for the maintenance of follicular viability after transplantation. The aim of this study was to evaluate and compare the application of L-Mesitran Soft(R), a product containing 40% medical grade honey (MGH), with other strategies to improve ovarian grafts' viability. For this purpose, bovine ovarian tissue was vitrified, warmed and randomly assigned to culture groups: (1) control, (2) MGH 0.2% in vitro, (3) MGH in vivo (direct application in the xenotransplantation), (4) vascular endothelial growth factor (VEGF 50 ng/mL) and (5) vitamin D (100 Nm), during a 48 h period. A sixth group (6) of fragments was thawed on transplantation day and was not cultured. The tissue was xenotransplanted into immunodeficient (Rowett nude homozygous) ovariectomized rats. Grafts were analyzed 48 h after culture, and 7 and 28 days after transplantation. The tissue was subjected to histological and immunohistochemical analysis. Treatments using MGH showed the highest angiogenic and cell proliferation stimulation, with cellular apoptosis, within a healthy cellular turnover pathway. In conclusion, MGH should be considered as a potentially effective and less expensive strategy to improve ovarian tissue transplantation.MDPISapientiaAzevedo, Ana RitaPais, Ana SofiaAlmeida-Santos, TeresaPires, Virgínia M. R.Pessa, PedroMarques, Carla C.Nolasco, SofiaCastelo-Branco, PedroPrates, José A. M.Lopes-da-Costa, LuísLaranjo, MafaldaBotelho, Maria FilomenaPereira, Rosa M. L. N.Pimenta, Jorge M. B. G. A.2023-01-04T11:14:29Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/18727eng10.3390/bioengineering90803572306-5354info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:31:02Zoai:sapientia.ualg.pt:10400.1/18727Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:08:28.248748Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Medical grade honey as a promising treatment to improve ovarian tissue transplantation
title Medical grade honey as a promising treatment to improve ovarian tissue transplantation
spellingShingle Medical grade honey as a promising treatment to improve ovarian tissue transplantation
Azevedo, Ana Rita
Xenografting
Ovarian
Vitrification
Honey
Fertility
Cryopreservation
title_short Medical grade honey as a promising treatment to improve ovarian tissue transplantation
title_full Medical grade honey as a promising treatment to improve ovarian tissue transplantation
title_fullStr Medical grade honey as a promising treatment to improve ovarian tissue transplantation
title_full_unstemmed Medical grade honey as a promising treatment to improve ovarian tissue transplantation
title_sort Medical grade honey as a promising treatment to improve ovarian tissue transplantation
author Azevedo, Ana Rita
author_facet Azevedo, Ana Rita
Pais, Ana Sofia
Almeida-Santos, Teresa
Pires, Virgínia M. R.
Pessa, Pedro
Marques, Carla C.
Nolasco, Sofia
Castelo-Branco, Pedro
Prates, José A. M.
Lopes-da-Costa, Luís
Laranjo, Mafalda
Botelho, Maria Filomena
Pereira, Rosa M. L. N.
Pimenta, Jorge M. B. G. A.
author_role author
author2 Pais, Ana Sofia
Almeida-Santos, Teresa
Pires, Virgínia M. R.
Pessa, Pedro
Marques, Carla C.
Nolasco, Sofia
Castelo-Branco, Pedro
Prates, José A. M.
Lopes-da-Costa, Luís
Laranjo, Mafalda
Botelho, Maria Filomena
Pereira, Rosa M. L. N.
Pimenta, Jorge M. B. G. A.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Azevedo, Ana Rita
Pais, Ana Sofia
Almeida-Santos, Teresa
Pires, Virgínia M. R.
Pessa, Pedro
Marques, Carla C.
Nolasco, Sofia
Castelo-Branco, Pedro
Prates, José A. M.
Lopes-da-Costa, Luís
Laranjo, Mafalda
Botelho, Maria Filomena
Pereira, Rosa M. L. N.
Pimenta, Jorge M. B. G. A.
dc.subject.por.fl_str_mv Xenografting
Ovarian
Vitrification
Honey
Fertility
Cryopreservation
topic Xenografting
Ovarian
Vitrification
Honey
Fertility
Cryopreservation
description Ovarian tissue cryopreservation is a female fertility preservation technique that presents major challenges for the maintenance of follicular viability after transplantation. The aim of this study was to evaluate and compare the application of L-Mesitran Soft(R), a product containing 40% medical grade honey (MGH), with other strategies to improve ovarian grafts' viability. For this purpose, bovine ovarian tissue was vitrified, warmed and randomly assigned to culture groups: (1) control, (2) MGH 0.2% in vitro, (3) MGH in vivo (direct application in the xenotransplantation), (4) vascular endothelial growth factor (VEGF 50 ng/mL) and (5) vitamin D (100 Nm), during a 48 h period. A sixth group (6) of fragments was thawed on transplantation day and was not cultured. The tissue was xenotransplanted into immunodeficient (Rowett nude homozygous) ovariectomized rats. Grafts were analyzed 48 h after culture, and 7 and 28 days after transplantation. The tissue was subjected to histological and immunohistochemical analysis. Treatments using MGH showed the highest angiogenic and cell proliferation stimulation, with cellular apoptosis, within a healthy cellular turnover pathway. In conclusion, MGH should be considered as a potentially effective and less expensive strategy to improve ovarian tissue transplantation.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01T00:00:00Z
2023-01-04T11:14:29Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/18727
url http://hdl.handle.net/10400.1/18727
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.3390/bioengineering9080357
2306-5354
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133330618187776